2Doç. Dr., Tepecik Eğitim ve Araştırma Hastanesi, Göz Hastalıkları, İzmir, Türkiye Aim: To evaluate the clinical fi ndings and the effi cacy of intravitreal ranibizumab injecton in vitrectomized eyes of patients with postoperative macular edema.
Methods: Seven PME patients, who consented to receive intravitreal ranibizumab injection and were followed regularly at least six months were included in the study. All patients underwent standard ophtalmological examination, fl uorescein angiography (FA), and optical coherence tomography (OCT). Best - corrected visual acuity (BCVA), central macular thickness (CMT) and intraocular pressures were recorded at baseline and at fi rst months after the injection. Statistical Package for the Social Sciences (SPSS) was used for statistical analysis. A p-value lower than 0.05 was taken as statistically significant
Results: Mean BCVA was 0.24± 0.18 at baseline and 0.45±0.18 after treatment. Compared with the baseline value, there was a signifi cant increase in mean BCVA with treatment (p=0.018) at the end of the follow-uo period.. CMT was 458.7± 55.4 ?m at baseline and 355.6±107.3 ?m after treatment. Compared with baseline, CMT signifi cantly reduced with treatment. (p=0.01)
Conclusion: Treatment of postoperative macular edema with intravitreal ranibizumab injection may reduce CSMT and may improve BCVA.
Keywords : Postvitrectomy macula edema, intravitreal ranibizumab injection, central macula thickness